A Phase I Study of Oral BGJ398 in Asian Patients

NCT01697605 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumor With Alterations of the FGF-R

Interventions

DRUG: BGJ398

Sponsor

Novartis Pharmaceuticals